Dato-DXd is an ADC targeting TROP2 and delivering a potent topoisomerase I inhibitor. Efficacy seen in prior reports but this presentation focused on the subset of patients with NSCLC harboring an actionable driver alteration. (Dr. Stephen V. Liu)
In driver+ NSCLC, Dato-DXd had a Response Rate (RR) of 35% with a median Duration of Response (DOR) of 9.5m. Activity seen post- TKI for EGFR and ALK. Small sample here but encouraging to see activity — yet another option worth investigation. A versatile agent that can fill an unmet need, though not clearly related to the fact that a driver is present. So maybe not more likely to respond but not less likely either. (Dr. Stephen V. Liu) Read more.